CD19

Across TCGA pan-cancer cohorts, CD19 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD19 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CD19 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CD19 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, LIHC, and ACC are the cancer types where CD19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.829	.020	14	view →
LIHC	OS	Median	III,IV	0.118	0.615	.003	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	All	0.919	0.731	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD19–UCEC (DFS)

Open the UCEC breakdown →